Hacioglu, MB; Kostek, O; Karabulut, S; Tastekin, D; Goksu, SS; Alandag, C; Akagunduz, B; Bilgetekin, I; Caner, B; Sahin, AB; Yildiz, B; Kose, F; Kaplan, MA; Gulmez, A; Dogan, E; Guven, DC; Gurbuz, M; Ergun, Y; Karaagac, M; Demiray, AG; Turker, S; Sakalar, T; Ozkul, O; Telli, TA; Sahin, S; Kilickap, S; Bilici, A; Erdogan, B; Cicin, I
(2020)
Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of ...